Abstract: Embodiments of the present disclosure relate to real-time digitally signing of a virtual object. The real-time digital signing of a virtual object is provided in a multi-user real-time context between signor and signee that enables the signor to perform the real-time digital signing and the signee to visually experience the real-time signing. The real-time digital signing may be provided to the signor and signee in parallel, and/or one or more additional viewers taking part in the digital signing. Upon completion of the digital signing, some embodiments in near-real-time generate a digital asset that is linked to the virtual object modified with the digital signature, which may be assigned to and/or otherwise linked with the signee for subsequent retrieval and/or use.

Abstract: Methods for treating a subject for arthritis are provided. Aspects of the methods include administration to the subject a rs419598/rs315952/rs9005-haplotype-informed therapeutic regimen. In some instances, the methods include administering to the subject a therapeutic regimen that antagonizes interleukin-1 (IL-1) activity and/or a disease modifying osteoarthritis drug (DMOAD) if the subject has been identified as having a TTG rs419598/rs315952/rs9005 haplotype. Also provided are compositions for use in practicing the methods.

Abstract: Hepatitis can be treated by administering to a patient in need thereof an effective amount of a compound that neutralizes the effects of secreted TNF-alpha.

Abstract: Hepatitis can be treated by administering to a patient in need thereof an effective amount of a compound that neutralizes the effects of secreted TNFalpha. Two types of these compounds are extracellular ligand binding proteins of the human p75 TNF receptor, such as etanercept (Enbrel), and humanized monoclonal antibodies that neutralize the activity of TNFalpha, such as inflixamab (Remicade).

Abstract: Agents with integrin-afffecting activity, including antibodies and molecules having the antigen-binding portion of such antibodies, are used to regulate inflammatory mediators, including TL-1&bgr;, IL-6, IL-8, nitric oxide, PGE2 and MMPs.

Abstract: Hepatitis can be treated by administering to a patient in need thereof an effective amount of a compound that neutralizes the effects of secreted TNFalpha. Two types of these compounds are extracellular ligand binding proteins of the human p75 TNF receptor, such as etanercept (Enbrel), and humanized monoclonal antibodies that neutralize the activity of TNFalpha, such as inflixamab (Remicade).

Abstract: Chemically modified tetracyclines are a new class of non-steroidal anti-inflammatory drugs which inhibit cyclooxygenase-2 and tumor necrosis factor alpha. These chemically modified tetracyclines are used in a method for inhibiting COX-2, which in turn inhibits PGE2, and/or inhibiting TNF&agr;. They are also used in a method for treating a disease or disorder associated with elevated activities of COX-2 (i.e., increased production of PGE2) and/or TNF&agr;.

Abstract: A protective screen with burglar alarm includes a full screen wired in a closed circuit fashion connected to a keyed box alarm. The unit is self-contained with each window having its own power source and alarm, including preferably audio and visual alarms. A magnetic connection is also provided so that if the screen is pushed out of its frame without actually cutting the screen, the alarm will sound.